B H Ebdrup

List of Publications by Year
in descending order

45 papers	1,077 citations	430874 18 h-index	434195 31 g-index
49 all docs	49 docs citations	49 times ranked	1807 citing authors

#	Article	IF	Citations
1	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naÃ¯ve schizophrenia patients aged 12â€“43 years. Psychological Medicine, 2021, 51, 1570-1580.	4.5	17
2	Multimodal assessment of white matter microstructure in antipsychotic-naÃ¯ve schizophrenia patients and confounding effects of recreational drug use. Brain Imaging and Behavior, 2021, 15, 36-48.	2.1	6
3	Associations between cognition and white matter microstructure in first-episode antipsychotic-naÃ¯ve patients with schizophrenia and healthy controls: A multivariate pattern analysis. Cortex, 2021, 139, 282-297.	2.4	5
4	Global fractional anisotropy predicts transition to psychosis after 12Âmonths in individuals at ultraâ€high risk for psychosis. Acta Psychiatrica Scandinavica, 2021, 144, 448-463.	4.5	9
5	Weight gain on antipsychotics â€“ A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatrica Scandinavica, 2021, 144, 521-523.	4.5	3
6	Gamma-hydroxybutyric acid-induced organic delirium complicated by polydrug use successfully treated with electroconvulsive therapy: a case report. Journal of Medical Case Reports, 2021, 15, 596.	0.8	2
7	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosisâ€”A Randomized Clinical Trial. Frontiers in Psychiatry, 2020, 11, 873.	2.6	9
8	A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naÃ¯ve schizophrenia patients based on multimodal neuropsychiatric data. Translational Psychiatry, 2020, 10, 276.	4.8	24
9	Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
10	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. Frontiers in Pharmacology, 2020, 11, 591.	3.5	8
11	Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-NaÃ¯ve Schizophrenia Patients. Frontiers in Neuroscience, 2020, 14, 484.	2.8	15
12	A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal of Psychopharmacology, 2020, 34, 524-531.	4.0	9
13	The Agents Intervening against Delirium in the Intensive Care Unit Trial (AIDâ€ICU trial): A detailed statistical analysis plan. Acta Anaesthesiologica Scandinavica, 2020, 64, 1357-1364.	1.6	7
14	Increased use of coercive procedures and prolonged hospitalization in compulsory admitted psychotic patients, who refuse antipsychotic medication. Nordic Journal of Psychiatry, 2020, 74, 323-326.	1.3	5
15	Phenotypic factors associated with amisulprideâ€induced weight gain in firstâ€episode psychosis patients (from the OPT iMi SE cohort). Acta Psychiatrica Scandinavica, 2019, 140, 283-290.	4.5	6
16	Agents intervening against delirium in the intensive care unit (AIDâ€ICU) â€“ Protocol for a randomised placeboâ€controlled trial of haloperidol in patients with delirium in the ICU. Acta Anaesthesiologica Scandinavica, 2019, 63, 1426-1433.	1.6	10
17	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultraâ€high risk for psychosis. Human Brain Mapping, 2019, 40, 5185-5201.	3.6	22
18	Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade â€“ An exploratory study. Psychiatry Research, 2019, 274, 58-65.	3.3	13

#	Article	IF	Citations
19	Glucagonâ€like peptideâ€1 receptor agonists for antipsychoticâ€associated cardioâ€metabolic risk factors: A systematic review and individual participant data metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 293-302.	4.4	69
20	Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naÃ¯ve schizophrenia patients. Psychological Medicine, 2019, 49, 2754-2763.	4.5	20
21	The impact of schizophrenia and intelligence on the relationship between age and brain volume. Schizophrenia Research: Cognition, 2019, 15, 1-6.	1.3	8
22	Patterns of Cortical Structures and Cognition in Antipsychotic-NaÃ¯ve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 444-453.	1.5	12
23	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naÃ¯ve first-episode schizophrenia patients. Psychological Medicine, 2019, 49, 868-875.	4.5	18
24	Adverse cardiac events in outâ€patients initiating clozapine treatment: a nationwide registerâ€based study. Acta Psychiatrica Scandinavica, 2018, 137, 47-53.	4.5	54
25	White matter maturation during 12 months in individuals at ultraâ€highâ€risk for psychosis. Acta Psychiatrica Scandinavica, 2018, 137, 65-78.	4.5	23
26	Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: A systematic review. Psychiatry Research - Neuroimaging, 2018, 282, 31-39.	1.8	13
27	Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. Frontiers in Psychiatry, 2018, 9, 781.	2.6	11
28	No cognitiveâ€enhancing effect of <scp>GLP</scp>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 52-62.	4.5	36
29	Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. Translational Psychiatry, 2017, 7, e1087-e1087.	4.8	32
30	Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. Psychological Medicine, 2017, 47, 2689-2707.	4.5	32
31	Selective attention and mismatch negativity in antipsychotic-naÃ¯ve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy. Psychological Medicine, 2017, 47, 2155-2165.	4.5	16
32	â€¯No cognitiveâ€enhancing effect of <scp>GLP</scp>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophreniaâ€™: authors' response. Acta Psychiatrica Scandinavica, 2017, 136, 526-527.	4.5	0
33	Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naÃ¯ve schizophrenia patients before and after initial antipsychotic treatment. World Journal of Biological Psychiatry, 2017, 18, 539-549.	2.6	4
34	Effect of <scp>GLP</scp>â€1 receptor agonist treatment on body weight in obese antipsychoticâ€treated patients with schizophrenia: <scp>a</scp> randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 162-171.	4.4	53
35	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. JAMA Psychiatry, 2016, 73, 121.	11.0	68
36	Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. Journal of Psychiatry and Neuroscience, 2016, 41, 133-141.	2.4	44

#	Article	IF	Citations
37	Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology, 2015, 60, 1-6.	2.7	8
38	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonistâ€"protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open, 2014, 4, e004158.	1.9	20
39	The influence of impaired processing speed on cognition in first-episode antipsychotic-naÃ¯ve schizophrenic patients. European Psychiatry, 2013, 28, 332-339.	0.2	38
40	Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes. American Journal of Psychiatry, 2013, 170, 681-682.	7.2	21
41	Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review. Current Medicinal Chemistry, 2013, 20, 438-447.	2.4	2
42	Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review. Current Medicinal Chemistry, 2013, 20, 438-447.	2.4	74
43	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Medicine, 2012, 10, 92.	5.5	24
44	Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. International Journal of Neuropsychopharmacology, 2011, 14, 69-82.	2.1	78
45	Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. Journal of Psychiatry and Neuroscience, 2010, 35, 95-104.	2.4	103